Why Oncotheryeon, Inc., OncoMed Pharmaceuticals, Inc., and Array BioPharma Inc. Stocks Jumped Today
Three biotechs climb after a competitor's trial success boosts hope across the HER-2 breast cancer treatment market
Why OncoMed Pharmaceuticals Inc. Shares Surged
OncoMed shares reverse course from Friday's swoon despite the release of mixed news from the company.
This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector
Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.
Down 9%: Is OncoMed a Bad News Buy?
OncoMed shares had a rough day. Time to buy?
Why OncoMed Pharmaceuticals Inc. Shares Collapsed
OncoMed shares dive after it voluntarily halts two early-stage programs. Find out what investors should be closely monitoring going forward.
How This 1 Company Is Attempting to Overcome One of Cancer's Greatest Risk Factors
This revolutionary biopharmaceutical company aims to get to the root of treating cancer rather than just scratching at the surface.
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
The five biotechs with the largest number of shares sold short as a percentage of float.
What You Ought To Know About Celgene's Deal-Making Magic
Celgene's investment team has made a string of savvy investments in early stage biotech companies.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.